Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

RTTNews | 411天前
Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24

(RTTNews) - German science and technology major Merck KgaA reported Thursday weak profit and sales in fiscal 2023 amid a challenging market environment. Higher sales in Healthcare business sector were more than offset by weakness in Life Science and Electronics.

Looking ahead for fiscal 2024, Merck expects return to organic growth with slight to moderate organic growth in sales and EBITDA pre, with Healthcare as the main driver.

Further, the Executive Board and Supervisory Board will propose to the Annual General Meeting on April 26 a dividend of 2.20 euros per share, same as last year.

Belen Garijo, Chair of the Executive Board and CEO of Merck, said, "Now, we are fully focusing on gradually returning to growth during fiscal 2024, while defining our strategic roadmap to ensure long term profitable and sustainable growth for Merck."

In fiscal 2023, profit after tax fell 15.1 percent to 2.83 billion euros from last year's 3.34 billion euros. Earnings per share were 6.49 euros, down 15.2 percent from last year's 7.65 euros.

On an adjusted basis, earnings per share pre were 8.49 euros, compared to last year's 10.05 euros.

Operating result or EBIT fell 19.3 percent to 3.61 billion euros from last year's 4.47 billion euros last year. EBIT margin was 17.2 percent, down from 20.1 percent last year.

EBITDA pre fell 14.2 percent year-over-year to 5.88 billion euros, EBITDA margin pre dropped to 28 percent from 30.8 percent last year.

Net sales for the year declined 5.6 percent to 20.99 billion euros from 22.23 billion euros a year ago. Group net sales decreased 1.6 percent organically.

According to the company, the weak results reflected difficult market conditions, including the significant decline in Covid-19-related demand as expected, persistent inventory destocking by key customers of Merck in Process Solutions, as well as the cyclical slowdown in demand for semiconductor materials.

Sales of the Life Science business sector decreased 10.6 percent from last year to 9.28 billion euros. In the Electronics business sector, sales decreased 8.8 percent. In the Semiconductor Solutions business unit, sales decreased organically by 3.9 percent.

Net sales of the Healthcare business sector increased 2.7 percent to 8.05 billion euros, and the growth was 8.5 percent organically.

In Germany, Merck KGaA shares were trading at 158.95 euros, up 0.41 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

read more
Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up

German science and technology major Merck KgaA Thursday reconfirmed its earnings and sales forecast for fiscal 2023, but at the lower half of the range after reporting weak profit and sales in its third quarter amid a difficult market environment. Further, the company projects a return to organic sales growth in fiscal 2024. The shares were gaining around 5 percent in the morning trading in German
RTTNews | 530天前
Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23

German science and technology major Merck KgaA reported Thursday higher profit and revenues in its fiscal 2022, with improved performance in all divisions. The company further lifted its dividend, and said it expects weak to flat EBITDA pre in fiscal 2023, but higher organic sales.
RTTNews | 782天前
Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average

While providing updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity on Monday, German science and technology firm Merck KGaA (MKGAY.PK) said it will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation.
RTTNews | 883天前
Roche To Invest $50 Bln In U.S; To Create 12,000 Jobs

Roche To Invest $50 Bln In U.S; To Create 12,000 Jobs

Amid the ongoing tariff issues, Swiss drug major Roche Holding AG announced its plan to invest $50 billion in the United States in the next five years, aiming to expand its Pharmaceutical and Diagnostics Divisions. With all new and expanded manufacturing capacity, Roche aims to export more medicines from the US than it imports.
RTTNews | 20分鐘前
Bay Street Likely To Open On Cautious Note

Bay Street Likely To Open On Cautious Note

The Canadian market is likely to open on a cautious note Tuesday morning, but some buying is likely in energy and materials sectors thanks to firm commodity prices. Worries about trade tensions and the stand-off between U.S. President and the Fed Chair might hurt sentiment and limit market's upside.
RTTNews | 21分鐘前
FTSE 100 Up Marginally; Sainsbury Rises After Announcing Buyback Program

FTSE 100 Up Marginally; Sainsbury Rises After Announcing Buyback Program

U.K. stocks are modestly higher on Tuesday, led by gains in retailers and consumer staples stocks, even as the mood remains cautious amid lingering concerns about global economic growth due to trade tensions following the U.S. government's highly protectionist trade policy.
RTTNews | 2小時6分鐘前
CAC 40 Down Marginally

CAC 40 Down Marginally

The French stock market is down marginally on Tuesday as investors, amid lingering concerns over U.S. Government's trade policy and rising tensions between the U.S. and China, largely remain cautious while awaiting some crucial economic data and earnings updates this week.
RTTNews | 2小時54分鐘前